Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2014

View Archived Issues

Korean patent details novel mutant haptoglobins

Screening of circulating patient-derived breast cancer cells for tailored treatment

uniQure acquires InoCard

Janssen describes different series of FLAP inhibitors for inflammatory diseases

Novel glucocorticoid receptor agonists show selectivity for transrepression over transactivation

G2B Pharma receives financing and right to in-license nasal delivery technologies

Galenica lays foundation for two independent companies

The Michael J. Fox Foundation for Parkinson's Research updates on its Partnering Program

Carfilzomib fails to meet primary endpoint in phase III multiple myeloma trial

U.S. DTRA supports preclinical development of Evolva's GC-072 for acute melioidosis

Novel nontreponemal EIA assay for the diagnosis of syphilis

Actelion Pharmaceuticals discloses new P2X7 antagonists

University of Toledo patents novel anticancer agents

Neuraceq launched in U.S.

New metalloenzyme inhibitors designed by Viamet Pharmaceuticals

Novartis disclose novel p53-Mdm2 interaction inhibitors

Skyepharma acquires rights to inhaled therapy platform from Pulmagen

Ligand Pharmaceuticals signs Captisol license agreement with Avion Pharmaceuticals

FDA grants fast track designation to SPN-810

FDA grants fast track designation to AG-221 for acute myelogenous leukemia

Miltenyi Biotec acquires Lentigen's lentiviral vector business

Ablynx awarded grant supporting nanobody development for ocular applications

BioCryst receives additional NIAID funding to advance development of BCX-4430

FDA accepts Pfizer's rLP-2086 BLA for review and grants priority review status

FDA approves Avastin in combination with chemotherapy for advanced cervical cancer

Questcor Pharmaceuticals acquired by Mallinckrodt

FDA approves Plegridy for relapsing multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026